Search Result

Results for "

and inflammatory bowel disease

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (2) Akt (1) Aminopeptidase (1) Antibiotic (3) Apoptosis (2) Bacterial (2) Calcium Channel (1) Cathepsin (1) CCR (2) CDK (2) COX (1) CX3CR1 (1) CXCR (5) Dihydroorotate Dehydrogenase (3) Drug Metabolite (1) E1/E2/E3 Enzyme (1) Epigenetic Reader Domain (1) FXR (2) GCGR (2) GLP Receptor (1) Glucocorticoid Receptor (2) Guanylate Cyclase (1) HIF/HIF Prolyl-Hydroxylase (2) HIV (2) IFNAR (1) IKK (1) Integrin (2) Interleukin Related (9) JAK (6) Leukotriene Receptor (3) Lipoxygenase (2) METTL3 (2) Na+/K+ ATPase (2) NF-κB (2) NO Synthase (2) NOD-like Receptor (NLR) (4) Orphan Receptor (1) P2Y Receptor (1) p38 MAPK (1) Phosphodiesterase (PDE) (3) PIKfyve (1) Potassium Channel (4) Proton Pump (2) RIP kinase (3) ROR (1) STAT (2) STING (1) TNF Receptor (4)
By Research Areas:	Cancer (10) Cardiovascular Disease (1) Endocrinology (1) Infection (5) Inflammation/Immunology (75) Metabolic Disease (9) Neurological Disease (3)

By Targets:

Adenosine Receptor (2)

Akt (1)

Aminopeptidase (1)

Antibiotic (3)

Apoptosis (2)

Bacterial (2)

Calcium Channel (1)

Cathepsin (1)

CCR (2)

CDK (2)

COX (1)

CX3CR1 (1)

CXCR (5)

Dihydroorotate Dehydrogenase (3)

Drug Metabolite (1)

E1/E2/E3 Enzyme (1)

Epigenetic Reader Domain (1)

FXR (2)

GCGR (2)

GLP Receptor (1)

Glucocorticoid Receptor (2)

Guanylate Cyclase (1)

HIF/HIF Prolyl-Hydroxylase (2)

HIV (2)

IFNAR (1)

IKK (1)

Integrin (2)

Interleukin Related (9)

JAK (6)

Leukotriene Receptor (3)

Lipoxygenase (2)

METTL3 (2)

Na+/K+ ATPase (2)

NF-κB (2)

NO Synthase (2)

NOD-like Receptor (NLR) (4)

Orphan Receptor (1)

P2Y Receptor (1)

p38 MAPK (1)

Phosphodiesterase (PDE) (3)

PIKfyve (1)

Potassium Channel (4)

Proton Pump (2)

RIP kinase (3)

ROR (1)

STAT (2)

STING (1)

TNF Receptor (4)

By Research Areas:

Cancer (10)

Cardiovascular Disease (1)

Endocrinology (1)

Infection (5)

Inflammation/Immunology (75)

Metabolic Disease (9)

Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Fat Mass and Obesity-associated Protein (FTO)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0174

Olsalazine Disodium	Leukotriene Receptor Antibiotic	Inflammation/Immunology
Olsalazine Disodium is an anti-inflammatory compound that works in inflammatory bowel disease and ulcerative colitis.

HY-107831

5-Acetylsalicylic acid 1 Publications Verification	Others	Inflammation/Immunology
5-Acetylsalicylic acid has anti-inflammatory and is considered to be the active agent in inflammatory bowel disease (IBD) .

HY-109182

Lorpucitinib JNJ-64251330	JAK	Inflammation/Immunology
Lorpucitinib is a Gut-Restricted JAK Inhibitor for the research of Inflammatory Bowel Disease .

HY-102013

Omilancor BT-11	Others	Neurological Disease Inflammation/Immunology
BT-11 is an orally available LANCL2 binding compound for treating inflammatory bowel disease.

HY-105092

Tetomilast OPC-6535	Phosphodiesterase (PDE)	Inflammation/Immunology
Tetomilast (OPC-6535) is a PDE4 inhibitor with potential for the research of inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD).

HY-13545B

ABT-510 acetate	Apoptosis	Inflammation/Immunology Cancer
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-107456

E6130 2 Publications Verification	CX3CR1	Inflammation/Immunology Endocrinology
E6130 is an orally active and highly selective CX3CR1 modulator, that may be effective for treatment of inflammatory bowel disease.

HY-W778340

16α-Hydroxy-11-keto prednisolone	Drug Metabolite Glucocorticoid Receptor	Inflammation/Immunology Cancer
16α-Hydroxy-11-keto prednisolone (compound M-X) is a metabolite of Budesonide (HY-13580). Budesonide, an inhaled glucocortical steroid, is an orally active glucocorticoid receptor agonist. Budesonide is a widely used for study of asthma, rhinitis, and inflammatory bowel disease .

HY-107015A

Prednisolone metazoate sodium Predfoam; ATL 2502	Glucocorticoid Receptor	Inflammation/Immunology
Prednisolone metazoate sodium (ATL 2502) can be used for study of inflammatory bowel disease, ulcerative colitis, and GI disorders .

HY-13545

ABT-510	Apoptosis	Inflammation/Immunology Cancer
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-B0174R

Olsalazine (Disodium) (Standard)	Leukotriene Receptor Antibiotic	Inflammation/Immunology
Olsalazine (Disodium) (Standard) is the analytical standard of Olsalazine (Disodium). This product is intended for research and analytical applications. Olsalazine Disodium is an anti-inflammatory compound that works in inflammatory bowel disease and ulcerative colitis.

HY-116164

A-79175	Lipoxygenase	Inflammation/Immunology
A-79175 is a potent 5-lipoxygenase inhibitor that inhibits leukotriene formation. A-79175 is promising for research of various allergic and inflammatory diseases including asthma, allergic rhinitis, rheumatoid arthritis and inflammatory bowel disease .

HY-117867A

AVE-8063 hydrochloride AC-7739	Others	Inflammation/Immunology
AVE-8063 (AC-7739) hydrochloride is a therapeutic agent associated with the modulation of inflammatory responses in inflammatory bowel disease (IBD), displaying mechanisms that may be relevant for precision targeting in current therapies.

HY-151435

CCR6 antagonist 1 2 Publications Verification	CCR	Inflammation/Immunology
CCR6 antagonist 1 is a CCR6 antagonist that inhibits the CCL20/CCR6 axis. CCR6 antagonist 1 can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs) .

HY-P3499

Dolcanatide	Guanylate Cyclase	Inflammation/Immunology
Dolcanatide is an orally active GC-C (guanylate cyclase-C) agonist. Dolcanatide shows laxative, anti-nociceptive and anti-inflammatory activity. Dolcanatide can be used in inflammatory bowel disease research .

HY-115744

Mercaptoethylguanidine (MEG) (dihydrobromide)	NO Synthase	Inflammation/Immunology
Mercaptoethylguanidine (MEG) dihydrobromide is selective inhibitor of the inducible nitric oxide synthase and peroxynitrite scavenger. Mercaptoethylguanidine (MEG) dihydrobromide has the potential for inflammatory bowel diseases research.

HY-102040

Hispidol 1 Publications Verification (Z)-Hispidol	TNF Receptor	Inflammation/Immunology
Hispidol ((Z)-Hispidol) is a potential therapeutic for inflammatory bowel disease; inhibits TNF-α induced adhesion of monocytes to colon epithelial cells with an IC₅₀ of 0.50 μM.

HY-16640

TCJL37	JAK	Inflammation/Immunology
TCJL37 is a potent, selective, and orally bioavailable TYK2 inhibitor with a K_i of 1.6 nM. TCJL37 can be used for the research of inflammatory bowel diseases (IBD) .

HY-167706

Diethyl-Lodoxamide	Others	Inflammation/Immunology
Diethyl-Lodoxamide is a highly potent GPR35 agonist with potential to inhibit inflammatory bowel disease. Diethyl-Lodoxamide activates GPR35 in humans, mice and rats, showing similar EC₅₀ values. Diethyl-Lodoxamide can alleviate the clinical symptoms of DSS-induced inflammatory bowel disease in mouse models, and the effect is better than the traditional drug 5-ASA. The pharmaceutical properties of Diethyl-Lodoxamide have been optimized to better meet the requirements of drug design .

HY-108017

Ferric maltol	Others	Metabolic Disease Cancer
Ferric maltol is an orally active complex of a single ferric ion (Fe ³⁺). Ferric maltol has tha potential for iron deficiency anemia treatment in inflammatory bowel disease .

HY-100278

AKP-001	p38 MAPK	Inflammation/Immunology
AKP-001 is an inhibitor of p38 mitogen-activated protein kinase (p38 MAPK). AKP-001 can inhibit the production of inflammatory cytokines and can be used for research in rheumatoid arthritis and inflammatory bowel disease .

HY-128063

CXCR3 antagonist 1	CXCR	Inflammation/Immunology
CXCR3 antagonist 1 (compound 6c) is a selective and non-cytotoxic CXCR3 antagonist (IC₅₀=0.06 µM). CXCR3 antagonist 1 has potential in researching inflammatory diseases (including inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and diabetes) .

HY-161757

Anti-inflammatory agent 86	Others	Inflammation/Immunology
Anti-inflammatory agent 86 is a Chrysin (HY-14589) derivative with anti-inflammatory effects. Anti-inflammatory agent 86 inhibits monocyte adhesion to colon epithelium induced by TNF-α, with an IC₅₀ of 4.71 μM. Anti-inflammatory agent 86 has the potential for the inflammatory bowel disease (IBD) research .

HY-N2549

(±)-Abscisic acid (±)-ABA	Calcium Channel	Metabolic Disease Inflammation/Immunology
(±)-Abscisic acid ((±)-ABA) is an orally active phytohormone. (±)-Abscisic acid induces Ca ²⁺ channel opening to facilitate the influx of calcium ions and modulates stomatal movement. (±)-Abscisic acid shows anti-inflammatory activity and has the potential for the research of inflammatory bowel disease (IBD) .

HY-137789

Tazofelone LY 213829	COX	Cancer
Tazofelone (LY 213829) is a cyclooxygenase-II (COX-II) inhibitor. Tazofelone transform into sulfoxide and quinol metabolites is primarily mediated by CYP3A. Tazofelone can be used for the research of inflammatory bowel disease .

HY-142834

RORγt/DHODH-IN-2	ROR Dihydroorotate Dehydrogenase	Inflammation/Immunology
RORγt/DHODH-IN-2 (compound 1) is a potent dual RORγt/DHODH inhibitor. RORγt/DHODH-IN-2 can be used for inflammatory bowel disease (IBD) research .

HY-P990876

Afimkibart PF-06480605; RVT-3101	TNF Receptor	Inflammation/Immunology
Afimkibart (PF-06480605) is a human IgG1 monoclonal antibody targeting tumor necrosis factor-like ligand 1A (TL1A). Afimkibart can be used in the research of inflammatory bowel disease .

HY-118795

SC-22716	Aminopeptidase	Inflammation/Immunology
SC-22716 is a potent, competitive, reversible inhibitor of human LTA₄ hydrolase, with an IC₅₀ of 0.20 µM. SC-22716 has potential for the research of inflammatory bowel disease (IBD) and psoriasis .

HY-P3507

Dalazatide ShK-186	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-112038A

GSK2983559	RIP kinase	Inflammation/Immunology
GSK2983559 is an orally active and potent receptor interacting protein 2 (RIP2) kinase inhibitor. GSK2983559 blocks many proinflammatory cytokine responses in vivo and in human inflammatory bowel disease explant samples .

HY-19667

BMS-561392 DPC 333	TNF Receptor	Inflammation/Immunology
BMS-561392 is a TNF alpha-converting enzyme (TACE) inhibitor. BMS-561392 is also an ADAM17 blocker. BMS-561392 can be used for research of inflammatory bowel disease .

HY-18263A

Elubrixin SB-656933	CXCR Interleukin Related	Inflammation/Immunology
Elubrixin (SB-656933) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin inhibits neutrophil CD11b upregulation (IC₅₀ of 260.7 nM) and shape change (IC₅₀ of 310.5 nM). Elubrixin has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation .

HY-18263C

Elubrixin tosylate SB-656933 tosylate	CXCR Interleukin Related	Inflammation/Immunology
Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin tosylate inhibits neutrophil CD11b upregulation (IC₅₀ of 260.7 nM) and shape change (IC₅₀ of 310.5 nM). Elubrixin tosylate has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation .

HY-18263

Elubrixin hydrochloride SB-656933 hydrochloride	CXCR Interleukin Related	Inflammation/Immunology
Elubrixin (SB-656933) hydrochloride is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin hydrochloride inhibits neutrophil CD11b upregulation (IC₅₀ of 260.7 nM) and shape change (IC₅₀ of 310.5 nM). Elubrixin hydrochloride has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation .

HY-P3507A

Dalazatide TFA ShK-186 TFA	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-147527

CDK8-IN-5	CDK	Inflammation/Immunology
CDK8-IN-5 is a potent CDK8 inhibitor with an IC₅₀ of 72 nM. CDK8-IN-5 shows anti-inflammatory activities with 43% IL-10 enhancement rate. CDK8-IN-5 has the potential for the research of inflammatory bowel disease .

HY-168591

CTSC-IN-1	Cathepsin	Cancer
CTSC-IN-1 (B22) is a CTSC inhibitor. CTSC-IN-1 inhibits CTSC activity by binding to S2 pocket and S1 site. CTSC-IN-1 can be used in the study inflammatory bowel disease .

HY-P99184

Abrilumab	Integrin	Infection Inflammation/Immunology Cancer
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .

HY-163498

NLRP3-IN-37	NOD-like Receptor (NLR)	Neurological Disease Inflammation/Immunology
NLRP3-IN-37 (Compound 23) is a NLRP3 inhibitor (EC₅₀: 5 nM). NLRP3-IN-37 can be used for NLRP3 related research, such as gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiophathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury .

HY-141521

Amelenodor NX-13	NOD-like Receptor (NLR)	Inflammation/Immunology
NX-13 is a first-in-class, orally active and gut-restricted agent that selectively targets and activates the NLRX1 pathway to induce immunometabolic changes. NX-13 results in lower inflammation and responses in inflammatory bowel disease. NX-13 can be used for the research of crohn's disease and ulcerative colitis .

HY-112038

GSK2983559 free acid	RIP kinase	Inflammation/Immunology
GSK2983559 free acid (compound 3) is an orally active and potent receptor interacting protein 2 (RIP2) kinase inhibitor. GSK2983559 free acid can block many proinflammatory cytokine responses in vivo and in human inflammatory bowel disease explant samples .

HY-P2221

Glepaglutide ZP1848	GCGR	Inflammation/Immunology
Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .

HY-P2221B

Glepaglutide acetate ZP1848 acetate	GCGR	Inflammation/Immunology
Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .

HY-158404

METTL3-IN-8	METTL3	Inflammation/Immunology
METTL3-IN-8 (7460-0250) is a potent METTL3 inhibitor. METTL3-IN-8 strongly ameliorates DSS-induced colitis. METTL3-IN-8 can be used Inflammatory bowel disease (IBD) research .

HY-15707

NS6180 1 Publications Verification	Potassium Channel	Inflammation/Immunology
NS6180 is a new orally active KCa3.1 channel inhibitor. NS6180 inhibits cloned human KCa3.1 channels with an IC₅₀value of 9 nM. NS6180 can be used for the research of inflammatory bowel disease (IBD) .

HY-12820

Sibofimloc 2 Publications Verification Antibiotic-202	Bacterial Antibiotic	Infection
Sibofimloc (Antibiotic-202) is a first-in-class, gut-restricted, orally active FimH adhesion inhibitor extracted from patent WO2014100158A1, Compound Example 202. Sibofimloc has anti-bacterial infective activity. Sibofimloc is developed for inflammatory bowel disease (IBD) .

HY-E70288

ST6 Sialyltransferase 6 ST6GALNAC6	Others	Inflammation/Immunology
ST6 Sialyltransferase 6 (ST6GALNAC6) belongs to the salivary transferase family, which modifies proteins and ceramides on the cell surface, thereby altering intercellular or extracellular matrix interactions. ST6 Sialyltransferase 6 can be used in the study of inflammatory bowel disease (IBD) .

HY-14908

Vidofludimus 4 Publications Verification 4sc-101; SC12267	Dihydroorotate Dehydrogenase Interleukin Related FXR	Infection Inflammation/Immunology
Vidofludimus is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus also can be used for the research of fatty liver by targeting FXR .

HY-P99486

Briakinumab ABT-874	Interleukin Related	Inflammation/Immunology
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .

HY-158403

METTL3-IN-7	METTL3	Inflammation/Immunology
METTL3-IN-7 (F039-0002) is a potent METTL3 inhibitor. METTL3-IN-7 strongly ameliorates dextran sodium sulfate (DSS)-induced colitis. METTL3-IN-7 can be used Inflammatory bowel disease (IBD) research .

Cat. No.	Product Name

HY-L078

Gut Microbial Metabolite Library

512 compounds

Accumulating evidence has revealed that intestinal microbiota play an important role in human health and disease, including cardiovascular diseases, inflammatory bowel disease, diabetes, obesity, cancer, and depression, etc. Changes in the composition of gut microbiota associated with disease, referred to as dysbiosis, have been linked to pathologies. Indeed, the gut microbiome functions like an endocrine organ, generating bioactive metabolites which play important roles in human metabolism, health, and disease. Gut microbiome has become a novel therapeutic target for many diseases. Analysis and identification of gut microbial metabolite will contribute to the development of therapeutic methods.

In order to meet the need of gut microbiome research, MCE carefully selected a unique collection of 512 gut microbial metabolites. MCE gut microbial metabolite library is a powerful tool for gut microbiome research and gut microbiome -related drug discovery.

HY-L014

NF-κB Signaling Compound Library

957 compounds

Nuclear factor-κB (NF-κB)/Rel proteins include NF-κB2 p52/p100, NF-κB1 p50/p105, c-Rel, RelA/p65, and RelB. These proteins function as dimeric transcription factors that regulate the expression of genes and influence a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. NF-κB plays a key role in regulating the immune response to infection. In addition, activation of the NF-κB pathway is involved in the pathogenesis of chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development.

MCE owns a unique collection of 957 small molecule compounds that can be used in the research of NF-κB signaling pathway or high throughput screening (HTS) related drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-13545B

ABT-510 acetate	Apoptosis	Inflammation/Immunology Cancer
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-P3499

Dolcanatide	Guanylate Cyclase	Inflammation/Immunology
Dolcanatide is an orally active GC-C (guanylate cyclase-C) agonist. Dolcanatide shows laxative, anti-nociceptive and anti-inflammatory activity. Dolcanatide can be used in inflammatory bowel disease research .

HY-P3507

Dalazatide ShK-186	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-P3507A

Dalazatide TFA ShK-186 TFA	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-P2221B

Glepaglutide acetate ZP1848 acetate	GCGR	Inflammation/Immunology
Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .

HY-P10587

Icotrokinra JNJ-77242113; JNJ-2113; PN-235	Interleukin Related STAT	Inflammation/Immunology
Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC₅₀=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC₅₀ of 18.4 pM. In addition, Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease .

HY-13545

ABT-510	Apoptosis	Inflammation/Immunology Cancer
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-P2221

Glepaglutide ZP1848	GCGR	Inflammation/Immunology
Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .

HY-P10842

d-GLP-2 E33A	GLP Receptor Akt	Metabolic Disease Inflammation/Immunology
d-GLP-2 E33A is an agonist for the glucagon-like peptide 2 receptor (GLP-2R) with an EC₅₀ of 414 nM. d-GLP-2 E33A can activate GLP-2R and increase the phosphorylation of AKT, but has no stimulative effect on GLP-1R. d-GLP-2 E33A can be used in the study of diseases such as intestinal malabsorption and inflammatory bowel diseases .

Cat. No.	Product Name	Target	Research Area

HY-P99389

Tesnatilimab	Inhibitory Antibodies	Inflammation/Immunology
Tesnatilimab is a human IgG4 monoclonal antibody that acts on the immune activating receptor NKG2D and has potential immunomodulatory and anti-inflammatory activity. Tesnatilimab can be used in the study of inflammatory bowel disease (IBD) .

HY-P990876

Afimkibart PF-06480605; RVT-3101	TNF Receptor	Inflammation/Immunology
Afimkibart (PF-06480605) is a human IgG1 monoclonal antibody targeting tumor necrosis factor-like ligand 1A (TL1A). Afimkibart can be used in the research of inflammatory bowel disease .

HY-P99184

Abrilumab	Integrin	Infection Inflammation/Immunology Cancer
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .

HY-P99486

Briakinumab ABT-874	Interleukin Related	Inflammation/Immunology
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .

HY-P9984

Etrolizumab 2 Publications Verification rhuMAb Beta7; RG7413; PRO145223	Integrin	Cancer
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with K_i values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2549

(±)-Abscisic acid (±)-ABA	Structural Classification Natural Products other families Classification of Application Fields Source classification Metabolic Disease Abscisic acid Plants Phytohormone Disease Research Fields Agricultural Research	Calcium Channel
(±)-Abscisic acid ((±)-ABA) is an orally active phytohormone. (±)-Abscisic acid induces Ca ²⁺ channel opening to facilitate the influx of calcium ions and modulates stomatal movement. (±)-Abscisic acid shows anti-inflammatory activity and has the potential for the research of inflammatory bowel disease (IBD) .

Cat. No.	Product Name	Chemical Structure

HY-17623S

Tegoprazan-d6

Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC₅₀ values ranging from 0.29-0.52 μM for porcine, canine, and human H ⁺/K ⁺-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks